Cellectis (XPAR:ALCLS) 10-Year Share Buyback Ratio : -8.10% (As of Mar. 2025)

View and export this data going back to 2007. Start your Free Trial

What is Cellectis 10-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Cellectis's current 10-Year Share Buyback Ratio was -8.10%.

XPAR:ALCLS's 10-Year Share Buyback Ratio is ranked better than
60.7% of 631 companies
in the Biotechnology industry
Industry Median: -11.7 vs XPAR:ALCLS: -8.10

Competitive Comparison of Cellectis's 10-Year Share Buyback Ratio

For the Biotechnology subindustry, Cellectis's 10-Year Share Buyback Ratio, along with its competitors' market caps and 10-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cellectis's 10-Year Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectis's 10-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Cellectis's 10-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Cellectis 10-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from ten years ago to the current year. The annualized percentage change is calculated with least-square regression based on the eleven years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Cellectis (XPAR:ALCLS) 10-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Cellectis 10-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of Cellectis's 10-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Cellectis Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (XPAR:ALCLS) » Definitions » 10-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

CMVLF:USA CLLS:USA 0WA2:UK ZVA:Germany

Address

8, rue de la Croix Jarry, Paris, FRA, 75013

Website

https://www.cellectis.com

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Cellectis Headlines

No Headlines